Maxcyte (MXCT) Current Deferred Revenue (2020 - 2026)

Maxcyte (MXCT) has 7 years of Current Deferred Revenue data on file, last reported at $3.3 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 21.09% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 21.09% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 31.48% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $3.3 million, down from $3.6 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for MXCT reached as high as $7.3 million in Q2 2022 and fell as low as $2.6 million in Q2 2025.
• Historically, Current Deferred Revenue has averaged $5.1 million across 5 years, with a median of $5.2 million in 2025.
• Across the five-year window, Current Deferred Revenue tumbled 35.81% in 2023 and advanced 19.1% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $6.7 million in 2022, then dropped by 24.49% to $5.1 million in 2023, then grew by 3.59% to $5.3 million in 2024, then sank by 31.48% to $3.6 million in 2025, then declined by 9.09% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $3.3 million in Q1 2026, $3.6 million in Q4 2025, and $5.2 million in Q3 2025.